Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX)
CUSIP: 45720N103
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 14,560,641
- Total 13F shares
- 10,435,616
- Share change
- -385,573
- Total reported value
- $148,917,132
- Price per share
- $14.27
- Number of holders
- 87
- Value change
- -$5,468,523
- Number of buys
- 30
- Number of sells
- 48
Quarterly Holders Quick Answers
What is CUSIP 45720N103?
CUSIP 45720N103 identifies INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 45720N103:
Top shareholders of INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP |
13F
|
Company |
12%
|
1,787,705
|
$25,009,993 | — | 31 Mar 2025 | |
| Sanofi |
13F
|
Company |
8%
|
1,157,926
|
$16,199,385 | — | 31 Mar 2025 | |
| Mark P. Lappe |
3/4/5
13D/G
|
Chief Executive Officer, Director · Mark Lappe |
6.4%
from 13D/G
|
1,225,413
mixed-class rows
|
$15,852,324 | — | 12 Sep 2024 | |
| Jon Faiz Kayyem |
3/4/5
13D/G
|
Director |
7.9%
from 13D/G
|
1,074,046
mixed-class rows
|
$15,030,087 | — | 28 May 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
7.3%
|
1,064,026
|
$14,885,723 | — | 31 Mar 2025 | |
| HighTower Advisors, LLC |
13F
|
Company |
6%
|
871,754
|
$12,195,838 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
5.7%
|
832,732
|
$11,649,920 | — | 31 Mar 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
4.8%
|
697,916
|
$9,763,845 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4%
|
588,323
|
$8,230,639 | — | 31 Mar 2025 | |
| PFM Health Sciences, LP |
13F
|
Company |
3%
|
439,283
|
$6,145,569 | — | 31 Mar 2025 | |
| Brendan P. Eckelman |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
648,888
mixed-class rows
|
$6,127,372 | — | 29 May 2024 | |
| Woodline Partners LP |
13F
|
Company |
2.5%
|
358,436
|
$5,014,520 | — | 31 Mar 2025 | |
| Slotnik Capital, LLC |
13F
|
Company |
2%
|
286,962
|
$4,014,598 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
260,029
|
$3,638,646 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.8%
|
255,336
|
$3,572,151 | — | 31 Mar 2025 | |
| Douglas G. Forsyth |
3/4/5
|
Director |
—
mixed-class rows
|
239,564
mixed-class rows
|
$3,159,615 | — | 28 May 2025 | |
| Caption Management, LLC |
13F
|
Company |
1.4%
|
199,508
|
$2,791,117 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
1.3%
|
192,498
|
$2,689,000 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.2%
|
172,904
|
$2,418,927 | — | 31 Mar 2025 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.1%
|
164,976
|
$2,308,014 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.99%
|
144,178
|
$2,017,050 | — | 31 Mar 2025 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
0.96%
|
139,682
|
$1,954,151 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.8%
|
116,513
|
$1,630,016 | — | 31 Mar 2025 | |
| Groupe la Francaise |
13F
|
Individual |
0.52%
|
75,932
|
$1,062,288 | — | 31 Mar 2025 | |
| CREDIT INDUSTRIEL ET COMMERCIAL |
13F
|
Individual |
0.44%
|
64,217
|
$898,396 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.36%
|
52,873
|
$739,693 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.36%
|
52,800
|
$738,672 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.33%
|
47,907
|
$670,219 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.29%
|
42,122
|
$589,287 | — | 31 Mar 2025 | |
| Alpha Wealth Funds, LLC |
13F
|
Company |
0.27%
|
38,647
|
$540,672 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.26%
|
37,347
|
$522,478 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.25%
|
36,900
|
$516,230 | — | 31 Mar 2025 | |
| Yakira Capital Management, Inc. |
13F
|
Company |
0.25%
|
36,195
|
$506,368 | — | 31 Mar 2025 | |
| Murchinson Ltd. |
13F
|
Company |
0.23%
|
33,790
|
$472,722 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.22%
|
32,657
|
$456,871 | — | 31 Mar 2025 | |
| Birchview Capital, LP |
13F
|
Company |
0.22%
|
32,110
|
$449,219 | — | 31 Mar 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.19%
|
28,230
|
$394,938 | — | 31 Mar 2025 | |
| Arbiter Partners Capital Management LLC |
13F
|
Company |
0.19%
|
28,095
|
$393,049 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.19%
|
27,468
|
$384,277 | — | 31 Mar 2025 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.19%
|
27,030
|
$378,149 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.18%
|
26,300
|
$367,937 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.17%
|
25,021
|
$350,044 | — | 31 Mar 2025 | |
| Meridian Wealth Advisors, LLC |
13F
|
Company |
0.17%
|
25,000
|
$349,750 | — | 31 Mar 2025 | |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Management |
13F
|
Company |
0.16%
|
22,584
|
$315,951 | — | 31 Mar 2025 | |
| Kristiina Vuori MD |
3/4/5
|
Director |
—
mixed-class rows
|
35,443
mixed-class rows
|
$306,645 | — | 28 May 2025 | |
| JBF Capital, Inc. |
13F
|
Company |
0.14%
|
20,949
|
$293,077 | — | 31 Mar 2025 | |
| Corient Private Wealth LLC |
13F
|
Company |
0.14%
|
20,455
|
$286,166 | — | 31 Mar 2025 | |
| Mariner, LLC |
13F
|
Company |
0.13%
|
18,667
|
$261,151 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.12%
|
17,930
|
$250,841 | — | 31 Mar 2025 | |
| Rangeley Capital, LLC |
13F
|
Company |
0.12%
|
17,810
|
$249,162 | — | 31 Mar 2025 |
Institutional Holders of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) as of Q2 2025
As of 30 Jun 2025,
Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) was held by
87 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,435,616 shares.
The largest 10 holders included
VIKING GLOBAL INVESTORS LP, Sanofi, PERCEPTIVE ADVISORS LLC, HighTower Advisors, LLC, BlackRock, Inc., Sofinnova Investments, Inc., Woodline Partners LP, VANGUARD GROUP INC, MILLENNIUM MANAGEMENT LLC, and PFM Health Sciences, LP.
This page lists
87
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
92
Q2 2025 holders
87
Holder diff
-5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.